Rosiglitazone Requires Hepatocyte PPARγ Expression to Promote Steatosis in Male Mice With Diet-Induced Obesity

Hepatocyte-specific loss of PPARγ protects mice from NASH, and increases the therapeutic effects of rosiglitazone in the liver.

(2021) Samuel M. Lee et al.   Cellular and Molecular Gastroenterology and Hepatology

Adipose tissue-liver cross talk in the control of whole-body metabolism: implications in non-alcoholic fatty liver disease

(2020) Vian Azzu et al.   GASTROENTEROLOGY

Characterization of the variability in the extent of nonalcoholic fatty liver induced by a high‐fat diet in the genetically diverse Collaborative Cross mouse model

(2020) Aline Conti et al.   FASEB JOURNAL

Loss of Hepatocyte-Specific PPARγ Expression Ameliorates Early Events of Steatohepatitis in Mice Fed the Methionine and Choline-Deficient Diet

(2020) Jose Cordoba-Chacon   PPAR Research

Diet Modifies Pioglitazone’s Influence on Hepatic PPARγ-Regulated Mitochondrial Gene Expression

(2020) Sakil Kulkarni et al.   PPAR Research

Genetic Liver-Specific AMPK Activation Protects against Diet-Induced Obesity and NAFLD

(2019) Daniel Garcia et al.   Cell Reports

Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the United States

(2019) Zobair M. Younossi et al.   DIABETES CARE

PPARγ deacetylation dissociates thiazolidinedione’s metabolic benefits from its adverse effects

(2018) Michael J. Kraakman et al.   JOURNAL OF CLINICAL INVESTIGATION

Mechanisms of NAFLD development and therapeutic strategies

(2018) Scott L. Friedman et al.   NATURE MEDICINE

Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis

(2018) Brian N. Finck   DIABETES

Non-alcoholic fatty liver disease – A global public health perspective

(2018) Zobair M. Younossi   JOURNAL OF HEPATOLOGY

Distinct but complementary contributions of PPAR isotypes to energy homeostasis

(2017) Vanessa Dubois et al.   JOURNAL OF CLINICAL INVESTIGATION

Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis

(2017) Giovanni Musso et al.   JAMA Internal Medicine

Dual Outcomes of Rosiglitazone Treatment on Fatty Liver

(2016) Mingming Gao et al.   AAPS Journal

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus

(2016) Kenneth Cusi et al.   ANNALS OF INTERNAL MEDICINE

Hepatic PPARγ Is Not Essential for the Rapid Development of Steatosis After Loss of Hepatic GH Signaling, in Adult Male Mice

(2016) Rhonda D. Kineman et al.   ENDOCRINOLOGY

Hepatocyte-specific, PPARγ-regulated mechanisms to promote steatosis in adult mice

(2016) Abigail Wolf Greenstein et al.   JOURNAL OF ENDOCRINOLOGY

Thiazolidinediones for nonalcoholic steatohepatitis

(2016) Lingling He et al.   MEDICINE

Growth Hormone Inhibits Hepatic De Novo Lipogenesis in Adult Mice

(2015) Jose Cordoba-Chacon et al.   DIABETES

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

(2015) Eduardo Vilar-Gomez et al.   GASTROENTEROLOGY

Differential impact of selective GH deficiency and endogenous GH excess on insulin-mediated actions in muscle and liver of male mice

(2014) Jose Cordoba-Chacon et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Thiazolidinediones and the Promise of Insulin Sensitization in Type 2 Diabetes

(2014) Raymond E. Soccio et al.   Cell Metabolism

A high-fat diet suppresses de novo lipogenesis and desaturation but not elongation and triglyceride synthesis in mice

(2014) Joao A. G. Duarte et al.   JOURNAL OF LIPID RESEARCH

Effects and Potential Mechanisms of Pioglitazone on Lipid Metabolism in Obese Diabetic KKAy Mice

(2014) Jun Peng et al.   PPAR Research

Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance

(2013) Chong Wee Liew et al.   NATURE MEDICINE

PPARγ signaling and metabolism: the good, the bad and the future

(2013) Maryam Ahmadian et al.   NATURE MEDICINE

Peripubertal-onset but not adult-onset obesity increases IGF-I and drives development of lean mass, which may lessen the metabolic impairment in adult obesity

(2012) Jose Cordoba-Chacon et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Nuclear receptor PPAR -regulated monoacylglycerol O-acyltransferase 1 (MGAT1) expression is responsible for the lipid accumulation in diet-induced hepatic steatosis

(2012) Y. J. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis

(2011) E. Boettcher et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts

(2011) Eva Morán-Salvador et al.   FASEB JOURNAL

Up-Regulation of PPAR-γ mRNA Expression in the Liver of Obese Patients: an Additional Reinforcing Lipogenic Mechanism to SREBP-1c Induction

(2011) Paulina Pettinelli et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Brain PPAR-γ promotes obesity and is required for the insulin–sensitizing effect of thiazolidinediones

(2011) Min Lu et al.   NATURE MEDICINE

Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C

(2010) Elena Lima-Cabello et al.   CLINICAL SCIENCE

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

(2009) Vlad Ratziu et al.   HEPATOLOGY

CellProfiler Analyst: data exploration and analysis software for complex image-based screens

(2008) Thouis R Jones et al.   BMC BIOINFORMATICS